Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02310542
Other study ID # 2010.652
Secondary ID
Status Completed
Phase N/A
First received November 14, 2014
Last updated February 27, 2018
Start date December 2011
Est. completion date September 30, 2017

Study information

Verified date February 2018
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A critical issue of the clinical syndrome in liver failure is the accumulation of toxins not cleared by the failing liver. Based on this hypothesis, albumin dialysis is used to remove those substances. Albumin dialysis with recirculation (MARS) is the most used system but required specific system and expert environment. Alternative system without recirculation (SPAD) is less expensive and can be realised in critical care services trained to extrarenal epuration. The primary objective of this study is to compare biological and clinical efficacy, pulsatility index of middle cerebral artery modification and tolerance of both systems.

This is a prospective, open, cross-over comparative study of two albumin dialysis system. Each patient will receive the two systems in an randomly assessed order. Patients are divided up according to bilirubin plasmatic level. (250µmol/L to 400 µmol/L and >400µmol/L).


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date September 30, 2017
Est. primary completion date September 30, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- severe hepatic failure on acute liver failure or acute on chronic liver failure

- hyperbilirubinemia (total plasmatic bilirubin level above 250µmol/L)

- hepatic encephalopathy or pruritus or hepatorenal syndrome.

- waiting for liver function recovery or liver transplantation

- Signed written informed consent by patient or patient's legally appointed representative or reliable person

- affiliation to social security

Exclusion Criteria:

- contraindication to extra-renal epuration

- hypersensibility to albumin or excipients

- patients for whom 2 albumin dialysis treatment cannot be considered

Study Design


Intervention

Device:
MARS albumin dialysis system

SPAD albumin dialysis system


Locations

Country Name City State
France Hôpital de la Croix Rousse - Service de réanimation chirurgicale LYON cedex 4

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of total plasmatic bilirubin level before and after two albumin dialysis systems : with recirculation (MARS™ system) and without recirculation (SPAD™ system) Determination of total plasmatic bilirubin level will be performed by arterial sample and expressed in µmol/liter. Total plasmatic bilirubin purification will be compared between the two dialysis systems: total plasmatic bilirubin level will be measured before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours. Before and at the end of a MARS™ dialysis (8h) and before and at the end of a SPAD™ system dialysis (10h). Participants will be followed for the duration of critical care stay, an expected average of 1 week
Secondary Comparison of bile acids and conjugated bilirubin levels before and after two albumin dialysis systems: with recirculation (MARS™ system) and without recirculation (SPAD™ system). Determination of bile acids and conjugated bilirubin levels will be performed by arterial sample and expressed in µmol/liter. Bile acids and conjugated bilirubin purifications will be compared between the two dialysis systems: Bile acids and conjugated bilirubin levels will be measured before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours. Before and at the end of a MARS™ system dialysis (8h) and before and at the end of a SPAD™ dialysis (10h) . Participants will be followed for the duration of critical care stay, an expected average of 1 week.
Secondary Comparison of hepatic encephalopathy score before and after two albumin dialysis systems : with recirculation (MARS™ system) and without recirculation (SPAD™ system) Determination of hepatic encephalopathy score will be performed by clinical evaluation. Hepatic encephalopathy score will be compared between the two dialysis systems: hepatic encephalopathy score will be measured before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours. Before and at the end of a MARS™ system dialysis (8h) and before and at the end of a SPAD™ system dialysis (10h) . Participants will be followed for the duration of critical care stay, an expected average of 1 week.
Secondary Comparison of pulsatility index of middle cerebral artery recorded by transcranial doppler before and after two albumin dialysis system : with recirculation (MARS™ system) and without recirculation (SPAD™ system) Pulsatility index of middle cerebral artery will be recorded by transcranial doppler. Pulsatility index of middle cerebral artery will be compared between the two dialysis systems: Pulsatility index of middle cerebral artery will be measured before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours. Before and at the end of a MARS™ dialysis (8h) and before and at the end of a SPAD™ system dialysis (10h). Participants will be followed for the duration of critical care stay, an expected average of 1 week
Secondary Comparison of tolerance of two albumin dialysis sytems : with recirculation (MARS™ system) and without recirculation (SPAD™ system) Tolerance will be evaluated by effect of albumin dialysis on coagulation indices : prothrombin time (seconds) and international normalized ratio, activated partial thromboplastin time ratio, fibrinogen level (g/L), factor V level (%), platelet count (×10(9) /L), hemoglobin level (g/L), red cell count (10(12)/L), hematocrit level (%). Coagulation indices will be measured by an arterial sample before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours. During MARS™ system dialysis (8h) and during SPAD™ system dialysis (10h) . Participants will be followed for the duration of critical care stay, an expected average of 1 week.
See also
  Status Clinical Trial Phase
Recruiting NCT00225901 - Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure Phase 1/Phase 2
Recruiting NCT01318525 - Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure Phase 2
Not yet recruiting NCT05778461 - Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure. N/A
Completed NCT03312036 - HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification N/A
Not yet recruiting NCT03084198 - Safety and Efficacy of hiHep Bioartificial Liver Support System to Treat Acute Liver Failure N/A
Recruiting NCT01341951 - Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis N/A
Not yet recruiting NCT05473403 - Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis N/A
Completed NCT04959110 - Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT N/A
Enrolling by invitation NCT01471262 - Right Hepatectomy in Patients Beyond 70 Years Old N/A
Recruiting NCT06263114 - Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients
Completed NCT04512014 - Perioperative Lactate Kinetics in Patient Undergoing Major Liver Surgery
Completed NCT02687763 - Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant Early Phase 1
Completed NCT01394497 - Use of N-Acetylcysteine During Liver Procurement Phase 2
Completed NCT01878305 - Neuromonitoring of Hepatic Encephalopathy N/A
Not yet recruiting NCT05817994 - Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Registry
Withdrawn NCT01137591 - Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever N/A